https://remotefirstjobs.com/companies/generate-biomedicines/jobs/associate-director-statistical-programming-768334
Associate Director, Statistical Programming at Generate:Biomedicines
Apply to Associate Director, Statistical Programming hiring by Generate:Biomedicines. Find Remote and Work from Home jobs in Data on Remote First Jobs.
associate directorstatistical programminggenerate biomedicines
https://www.cmlviz.com/stocks/GENB
GENB - Generate Biomedicines Inc Quote, Price, Charts & News - CMLViz.com
GENB Stock Price | Generate Biomedicines Inc(XNAS:GENB) stock summaries, charts and news
generate biomedicinesprice chartsincquotenews
https://stocknews.ai/ai-news/generate-biomedicines-inc-reports-first-quarter-2026-financial-results-and-provides-business-update/69fc6c2588d02a4cade20e48
Generate Biomedicines, Inc. Reports First Quarter 2026 Financial Results and Provides Business...
SOLAIRIA-1 AND SOLAIRIA-2 Phase 3 clinical trials for GB-0895 (anti-TSLP) continue to advanceClinical trial sites activated for GB-4362 (MMAE neutralizer);...
generate biomedicinesfirst quarterfinancial resultsincreports
https://www.renaissancecapital.com/Profile/GENB/Generate-Biomedicines/IPO
Generate Biomedicines: GENB IPO, Health Care - Phase 3 biotech using AI to develop therapies for...
IPO: Generate Biomedicines (GENB) - Phase 3 biotech using AI to develop therapies for immunology and oncology. - Health Care - Renaissance Capital
generate biomedicineshealth careusing aiipophase
https://www.biopharmaapac.com/news/80/5678/south-korea-invests-in-generate-biomedicines-through-samsung-to-drive-global-biopharma-innovation-.html
South Korea invests in Generate Biomedicines through Samsung to drive global biopharma innovation.
South Korea invests in Generate Biomedicines through Samsung to drive global biopharma innovation.
south koreagenerate biomedicinesinvestssamsungdrive
https://mfam.com.au/research-us/generate-biomedicines-genb/
[BUY] Generate Biomedicines (NASDAQ: GENB) - AI Biotech
Apr 27, 2026 - Rated Buy with a $26.00 target and 107.7% upside. AI-designed proteins and a 20x superior asthma biologic make GENB a standout clinical-stage opportunity.
generate biomedicinesbuynasdaqaibiotech
https://www.massbio.org/members/generate-biomedicines/
Generate Biomedicines - MassBio
May 4, 2026 - Research and Development in protein design.
generate biomedicinesmassbio
https://bullishdaily.com/news/generate-biomedicines-400m-ipo-biotech-revival-ai-drug-discovery
Generate Biomedicines Raises $400M in Blockbuster IPO, Signaling Biotech Revival Amid AI Drug...
Generate Biomedicines priced its $400M IPO at $16/share, capping a strong February with $1.4B in biotech IPO proceeds. The AI-driven firm advances GB-0895 in...
generate biomedicinesblockbusteriposignalingbiotech
https://biohired.com/jobs/39727
Member of Technical Staff, Vibe Labs at Generate Biomedicines in Somerville, MA | Biohired
Apply for Member of Technical Staff, Vibe Labs at Generate Biomedicines in Somerville, MA. Generative AI-powered protein therapeutics company designing novel...
member oftechnical staffgenerate biomedicinesvibelabs